Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04486352 | RECRUITING | Endometrial Cancer

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Sponsor:

Alliance Foundation Trials, LLC.

Brief Summary:

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

Condition or disease

Endometrial Cancer

Intervention/treatment

Atezolizumab - 28 Day Cycle

Bevacizumab

Ipatasertib

Talazoparib

Trastuzumab emtansine

Tiragolumab

Atezolizumab - 21 Day Cycle

Inavolisib

Letrozole

Giredestrant

Abemaciclib

Phase

PHASE1

PHASE2

Detailed Description:

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participants with recurrent and/or persistent endometrial cancer. This biomarker-driven study provides a platform whereby participants with persistent/recurrent endometrial cancer will be placed into study cohorts evaluating targeted agents selected on the basis of the tumor's specific genomic profile. Prospective participants with persistent and/or recurrent endometrial cancer will be prescreened within 60 days of treatment assignment to have a tumor tissue sample submitted for next-generation sequencing (NGS) using FoundationOne® companion diagnostic (CDx) testing prior to entering screening. If a participant has FoundationOne® CDx testing within five years of enrollment, the previous tumor tissue may be re-analyzed for use in the study. Non-FMI NGS testing may be submitted if approved. Depending on the cohort assignment per the tumor's biomarker profile, participants will be assigned to the AFT-50A Protocol (atezolizumab+targeted agent) or the AFT-50B Protocol (non-atezolizumab targeted agents). The current study cohorts are as follows: AFT-50A Cohorts * Atezolizumab + Bevacizumab doublet - Closed to Accrual * Atezolizumab + Ipatasertib doublet - Closed to Accrual * Atezolizumab + Talazoparib doublet * Atezolizumab + Trastuzumab emtansine (TDM-1) doublet - Closed to Accrual * Atezolizumab + Tiragolumab doublet - Closed to Accrual AFT-50B Cohorts * Inavolisib + Letrozole doublet * Giredestrant + Abemaciclib doublet It is anticipated that approximately 20 participants will be enrolled in each study cohort in AFT-50A and 24 participants in each study cohort in AFT-50B, unless otherwise specified for a given cohort due to statistical considerations. Each study cohort will open/close independently of other study cohorts. Once a study cohort reaches the prespecified number of participants, it will be closed to further enrollment, unless an expansion phase is planned. The study is structured to allow for additional cohorts to be added as the study progresses. These additional study cohorts may be proposed by investigators, but requires approval by the Steering Committee in order to be added to the protocol.

Study Type : INTERVENTIONAL
Estimated Enrollment : 148 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Actual Study Start Date : 2021-10-20
Estimated Primary Completion Date : 2026-10-01
Estimated Study Completion Date : 2027-10

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers:
Criteria
Key Inclusion Criteria
  • * Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy. Prior hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit. Chemotherapy given in conjunction with radiotherapy as a radiosensitizer will be counted as a systemic therapeutic regimen.
  • * Measurable disease per RECIST 1.1
  • * Availability of a representative tumor specimen that is suitable for determination of biomarker status via central testing (F1CDx) OR If a patient has a prior F1CDx report from 1 September 2019 or later, those NGS results can be used to determine biomarker status as long as the tumor tissue used in the report was obtained within 5 years prior to prescreening and appropriate signed consent is obtained from the patient.
  • * Life expectancy \> 12 weeks
  • * Recovery from effects of recent radiotherapy, surgery, or chemotherapy
  • Key Exclusion Criteria
    • * Endometrial tumors with the following histologies: squamous carcinomas, sarcomas
    • * Other invasive malignancies within the last 5 years, except for non-melanoma skin cancer with no evidence of disease within the past 5 years AND localized breast cancer with previous adjuvant chemotherapy treatment for breast cancer completed \> 5 years ago
    • * Synchronous primary invasive ovarian or cervical cancer
    • * Have an active or history of autoimmune disease or immune deficiency
    • * Have a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis based on a screening chest computed tomography (CT) scan
    • * Active tuberculosis
    • * Severe infections within 4 weeks
    • * Have received therapeutic oral or IV antibiotic medication within 2 weeks, except prophylactic antibiotic medication
    • * Have significant cardiovascular disease
    • * Are administered treatment with a live attenuated vaccine within 4 weeks, or anticipation of need for such a vaccine during the course of the study
    • * Have prior allogeneic bone marrow transplantation or solid organ transplant
    • * History of treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to initiation of study treatment
    • * History of treatment with systemic immunosuppressive medications within 2 weeks except acute, low-dose, systemic immunosuppressant medications, corticosteroids for chronic obstructive pulmonary disease and asthma, or mineralocorticoids and low-dose corticosteroids for participants with orthostatic hypotension or adrenocortical insufficiency
    • * Have a history or clinical evidence of any untreated CNS disease, seizures not controlled with standard medical therapy, or history of cerebrovascular accident (stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months
    • AFT-50A Specific Exclusion Criteria
      • ● Prior treatment with T-cell costimulating or immune checkpoint blockade therapies including, but not limited to, CD137 agonists, anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies
      • Note: Additional study cohort specific inclusion and exclusion criteria may apply based on cohort assignment.
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Location Details

NCT04486352

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

ACTIVE NOT RECRUITING

United States, California

City of Hope Comprehensive Cancer Center

Duarte, California, United States, 91010

ACTIVE NOT RECRUITING

United States, California

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States, 94143

ACTIVE NOT RECRUITING

United States, District of Columbia

Medstar Georgetown Cancer Institute

Washington D.C., District of Columbia, United States, 20007

ACTIVE NOT RECRUITING

United States, Florida

Mount Sinai Comprehensive Cancer Center

Miami Beach, florida, United States, 33140

ACTIVE NOT RECRUITING

United States, Illinois

University of Chicago

Chicago, Illinois, United States, 60637

ACTIVE NOT RECRUITING

United States, Kansas

University of Kansas Cancer Center

Westwood, Kansas, United States, 66205

ACTIVE NOT RECRUITING

United States, Maine

Maine Medical Center

Scarborough, Maine, United States, 04074

ACTIVE NOT RECRUITING

United States, Massachusetts

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02125

ACTIVE NOT RECRUITING

United States, Minnesota

University of Minnesota

Minneapolis, Minnesota, United States, 55455

WITHDRAWN

United States, Missouri

Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, United States, 63110

ACTIVE NOT RECRUITING

United States, Nebraska

Nebraska Methodist Hospital

Omaha, Nebraska, United States, 68114

ACTIVE NOT RECRUITING

United States, New Jersey

Englewood Health

Englewood, New Jersey, United States, 07631

ACTIVE NOT RECRUITING

United States, New Jersey

Atlantic Health Systems/Morristown Medical Center

Morristown, New Jersey, United States, 07960

ACTIVE NOT RECRUITING

United States, New York

Roswell Park

Buffalo, New York, United States, 14263

ACTIVE NOT RECRUITING

United States, New York

Weill Cornell Medicine

New York, New York, United States, 10065

ACTIVE NOT RECRUITING

United States, North Carolina

Duke University Cancer Center

Durham, North Carolina, United States, 27710

RECRUITING

United States, Oklahoma

University of Oklahoma Health Stephenson Cancer Center

Oklahoma City, Oklahoma, United States, 73104

ACTIVE NOT RECRUITING

United States, Oregon

Providence Portland Cancer Institute

Portland, Oregon, United States, 97213

ACTIVE NOT RECRUITING

United States, Pennsylvania

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15261

ACTIVE NOT RECRUITING

United States, Rhode Island

Lifespan - Rhode Island Hospital

Providence, Rhode Island, United States, 02903

WITHDRAWN

United States, Tennessee

Baptist Memorial Hospital

Memphis, Tennessee, United States, 38120